Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 14 December 2001:
Vol. 294. no. 5550, pp. 2268 - 2269
DOI: 10.1126/science.294.5550.2268b
Prev | Table of Contents | Next

News of the Week

GENE THERAPY:
Panel Reviews Risks of Germ Line Changes

Eliot Marshall

A high-profile experiment using gene therapy to treat hemophilia B has been on hold for 3 months because of concerns that it might alter the inheritable, or "germ line," DNA of patients in the trial. Last week, those concerns got their first public airing at a meeting of the Recombinant DNA Advisory Committee of the National Institutes of Health. The session did not yield a clear decision, but several panel members indicated that they thought the research should be allowed to resume.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)